<DOC>
	<DOCNO>NCT01957319</DOCNO>
	<brief_summary>Background : Hepatitis C virus infection interferon treatment show risk factor depression , distress , psychosocial burden poor health-related quality life . Aim : To determine effect Sylibin-vitamin E-phoshpolipids complex work ability whether health relate factor ( anxiety depression ) associate work ability subject chronic hepatitis C treat Peg-IFN-α RBV . Patients Methods : In prospective , randomize , placebo control , double blind clinical trial , 31 subject ( Group A ) chronic hepatitis , receive Pegylated-Interferon-α2b ( 1.5 mg/kg per week ) plus Ribavirin placebo , 31 subject ( Group B ) receive dosage Pegylated-Interferon-α2b plus Ribavirin plus association Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg one pill 12 month . All subject underwent laboratory exam questionnaire evaluate depression ( Beck Depression Inventory - BDI ) , anxiety ( State-trait anxiety inventory - STAI ) work ability ( Work ability Index - WAI ) .</brief_summary>
	<brief_title>Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression Increases Work Ability</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Silybin</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>HCV infection cancer severe jaundice pulmonary renal chronic disease prostatic disease autoimmune disease diabetes mellitus decompensated cirrhosis pregnancy hemoglobinopathy hemocromatosis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>